EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies

Isabella J Tan iD, Alicia Podwojniak iD, Aarushi Parikh, Bernard A Cohen

Current Issues in Molecular Biology · 30.03.2024 · 46 (4) · 2975-2990

DOI: 10.3390/cimb46040186 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 30.03.2024. Verfasst von Isabella J Tan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Robert Wood Johnson Medical School, 125 Paterson Steet, New Brunswick, NJ 08901, USA. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evolution of personalized medicine in dermatology signifies a transformative shift towards individualized treatments, driven by the integration of biomarkers. These molecular indicators serve beyond diagnostics, offering insights into disease staging, prognosis, and therapeutic monitoring. Specific criteria guide biomarker selection, ensuring attributes like specificity, sensitivity, cost feasibility, stability, rapid detection, and reproducibility. This literature review, based on data from PubMed, SCOPUS, and Web of Science, explores biomarkers in Hidradenitis Suppurativa (HS), Psoriasis, Atopic Dermatitis (AD), Alopecia Areata (AA), Vitiligo, and Chronic Spontaneous Urticaria (CSU). In HS, TNF-α, IL-1β, and MMPs serve as biomarkers, influencing targeted therapies like adalimumab and anakinra. Psoriasis involves biomarkers such as TNF-α, IL-23, and HLA genes, shaping treatments like IL23 and IL17 inhibitors. AD biomarkers include ECP, IL-4, IL-13, guiding therapies like dupilumab and tralokinumab. For AA, lipocalin-2, cytokines, and genetic polymorphisms inform JAK inhibitors’ use. Vitiligo biomarkers range from cytokines to genetic markers like TYR, TYRP1, guiding treatments like JAK inhibitors. CSU biomarkers encompass IgE, cytokines, and autologous serum tests, influencing therapies like omalizumab and cyclosporine. Comparing conditions, common proinflammatory markers reveal limited specificity. While some biomarkers aid diagnosis and standard treatments, others hold more scientific than clinical value. Precision medicine, driven by biomarkers, has shown success in skin malignancies. Future directions involve AI-powered algorithms, nanotechnology, and multi-omics integration for personalized dermatological care.

Schlagwörter

Stichwörter der Autor:innen

biomarker-driven therapiesmolecular insightspersonalized dermatology

Autor:innen und Institutionen

  • Rutgers Robert Wood Johnson Medical School, 125 Paterson Steet, New Brunswick, NJ 08901, USA.
  • Rowan-Virtua School of Osteopathic Medicine, 113 E Laurel Road, Stratford, NJ 08084, USA.
  • Department of Dermatology, The Johns Hopkins Hospital, Baltimore, MD 21287, USA.

ORCID-Profile: Isabella J Tan, Alicia Podwojniak

Zitieren

APA

Tan, I. J., Podwojniak, A., Parikh, A., & Cohen, B. A. (2024). Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies. Current Issues in Molecular Biology, 46(4), 2975-2990. https://doi.org/10.3390/cimb46040186

Vancouver

Tan IJ, Podwojniak A, Parikh A, Cohen BA. Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies. Current Issues in Molecular Biology. 2024;46(4):2975-2990. doi:10.3390/cimb46040186

BibTeX
@article{Tan2024,
  author = {Tan, Isabella J and Podwojniak, Alicia and Parikh, Aarushi and Cohen, Bernard A},
  title = {Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies},
  journal = {Current Issues in Molecular Biology},
  year = {2024},
  volume = {46},
  number = {4},
  pages = {2975--2990},
  doi = {10.3390/cimb46040186}
}
Kostenlos starten →